. 2007 Feb 27;105(Suppl 1):19–29. doi: 10.1007/s10549-007-9527-6

Table 1.

Time to progression in different patient subgroups [57]

Subgroup		Letrozole	Tamoxifen
Dominant disease site: soft tissue	n	113	115
Dominant disease site: soft tissue	Median TTP	12.1 months	6.4 months
Dominant disease site: bone	n	145	131
Dominant disease site: bone	Median TTP	9.5 months	6.3 months
Dominant disease site: viscera	n	195	208
Dominant disease site: viscera	Median TTP	8.3 months	4.6 months
Patients who had	n	94	83
received prior	Median TTP	8.9 months	5.9 months
antiestrogen	Hazard ratio (95% CI)^a	0.60 (0.43, 0.84)
HR-positive	n	294	305
	Median TTP	9.4 months	6.0 months
	Hazard ratio (95% CI)^a	0.69 (0.58, 0.83)
HR-unknown	n	159	149
	Median TTP	9.2 months	6.0 months
	Hazard ratio (95% CI)^a	0.77 (0.60, 0.99)

TTP, time to progression; CI, confidence interval; HR, hormone receptor

^aHazard ratios < 1.0 indicate superiority for letrozole relative to tamoxifen